Jury sides with Amphastar in patent case against Momenta

Amphastar Pharmaceuticals has succeeded in a jury trial against biotech company Momenta Pharmaceuticals and Sandoz, providing Amphastar with a way out of a patent suit over a blood thinning drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Sanofi-Aventis gets $17.2m in fees from failed Amphastar suit

6 May 2021 Sanofi-Aventis has been awarded $17.2 million in attorney fees, legal expenses and interest in a district court ruling on a failed suit levied by Amphastar Pharmaceuticals.

Big Pharma

Amphastar enters into $59m settlement with Sandoz and Momenta

20 June 2019 US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Jury sides with Amphastar in patent case against Momenta

More on this story

Editor's picks

Editor's picks

More features